NEW YORK (AP) — Turing Pharmaceuticals, the company formerly led by pharma bad boy Martin Shkreli, says it has cut jobs, "realigned its business priorities" and is looking for a new permanent CEO.
Shkreli resigned Friday, a day after his arrest on charges of securities fraud related to a company he previously ran.
He had been reviled for hiking the price of Daraprim by 5,000 percent. It's the only approved drug for toxoplasmosis, a life-threatening parasitic infection that mainly strikes pregnant women, cancer patients and AIDS patients.
A man who on Tuesday answered the number listed on the press release refused to give his name and would not comment on how many people were laid off. An email asking if Turing would cut the price of Daraprim was not immediately answered.